Prognostic Impact of Soluble CD163 in Patients with Diffuse Large B-cell Lymphoma

Overview

Journal Haematologica

Specialty Hematology

Date 2021 Mar 25

PMID 33764002

Citations 4

Authors

Heli Vajavaara

Frida Ekeblad

Harald Holte

Judit Jorgensen

Suvi-Katri Leivonen

Mattias Berglund

Peter Kamper

Holger J Moller

Francesco DAmore

Daniel Molin

Gunilla Enblad

Maja Ludvigsen

Ingrid Glimelius

Sirpa Leppa

Affiliations

Soon will be listed here.

Citing Articles

Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom's Macroglobulinemia: Emphasis on Asymptomatic WM.

Gkiokas A, Papadatou-Gigante M, Gkioka A, Koudouna A, Tryfou T, Alexandropoulos A Cells. 2025; 14(4).

PMID: 39996747 PMC: 11853255. DOI: 10.3390/cells14040275.

Same-Slide Spatial Multi-Omics Integration Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Yeo Y, Chang Y, Qiu H, Yiu S, Michel H, Wu W bioRxiv. 2025; .

PMID: 39764057 PMC: 11702642. DOI: 10.1101/2024.12.20.629650.

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.

Nikkarinen A, Lokhande L, Amini R, Jerkeman M, Porwit A, Molin D Blood Adv. 2023; 7(18):5304-5313.

PMID: 37389827 PMC: 10506048. DOI: 10.1182/bloodadvances.2023010052.

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma.

Stuhr L, Madsen K, Johansen A, Chen I, Hansen C, Jensen L Cancers (Basel). 2023; 15(3).

PMID: 36765852 PMC: 9913074. DOI: 10.3390/cancers15030897.

Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma.

Vajavaara H, Leivonen S, Jorgensen J, Holte H, Leppa S EJHaem. 2022; 3(3):681-687.

PMID: 36051040 PMC: 9421995. DOI: 10.1002/jha2.409.

References

Autio M, Leivonen S, Bruck O, Mustjoki S, Jorgensen J, Karjalainen-Lindsberg M . Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2020; 106(3):718-729. PMC: 7927991. DOI: 10.3324/haematol.2019.243626. View

Harrysson S, Eloranta S, Ekberg S, Enblad G, Jerkeman M, Wahlin B . Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021; 11(1):9. PMC: 7791057. DOI: 10.1038/s41408-020-00403-1. View

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlstrom H . U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol. 2017; 57(2):187-194. DOI: 10.1080/0284186X.2017.1337926. View

Andersen M, Abildgaard N, Maniecki M, Moller H, Andersen N . Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol. 2014; 93(1):41-7. DOI: 10.1111/ejh.12296. View

Moller H . Soluble CD163. Scand J Clin Lab Invest. 2011; 72(1):1-13. DOI: 10.3109/00365513.2011.626868. View

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M . Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(14):2373-80. DOI: 10.1200/JCO.2009.26.2493. View

Kridel R, Steidl C, Gascoyne R . Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica. 2015; 100(2):143-5. PMC: 4803134. DOI: 10.3324/haematol.2015.124008. View

Salles G, Barrett M, Foa R, Maurer J, OBrien S, Valente N . Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017; 34(10):2232-2273. PMC: 5656728. DOI: 10.1007/s12325-017-0612-x. View

Wada N, Zaki M, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y . Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology. 2012; 60(2):313-9. DOI: 10.1111/j.1365-2559.2011.04096.x. View

10.

Nederby L, Roug A, Knudsen S, Skovbo A, Kjeldsen E, Moller H . Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(11):3219-21. DOI: 10.3109/10428194.2015.1026899. View

11.

Leppa S, Jorgensen J, Tierens A, Meriranta L, Ostlie I, de Nully Brown P . Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020; 4(9):1906-1915. PMC: 7218416. DOI: 10.1182/bloodadvances.2020001518. View

12.

Sun N, Zhao J, Qiao W, Wang T . Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis. Biomed Res Int. 2015; 2015:648572. PMC: 4331162. DOI: 10.1155/2015/648572. View

13.

Kurtz D, Scherer F, Jin M, Soo J, Craig A, Shahrokh Esfahani M . Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018; 36(28):2845-2853. PMC: 6161832. DOI: 10.1200/JCO.2018.78.5246. View

14.

Mosser D . The many faces of macrophage activation. J Leukoc Biol. 2003; 73(2):209-12. DOI: 10.1189/jlb.0602325. View